News

During a live event, Kristen M. Pettit, MD, discussed the potential of using treatment earlier in polycythemia vera to alter the disease course.

During a live event, Julia Rotow, MD, and participants discussed how community oncologists are managing chemotherapy-induced neutropenia in extensive-stage small cell lung cancer.

FDA approves sacituzumab govitecan-hziy alone or with pembrolizumab as first-line therapy for unresectable/metastatic triple-negative breast cancer.

FDA approves palbociclib plus trastuzumab, with/without pertuzumab, and endocrine therapy as maintenance for HR+, HER2+ advanced breast cancer.

Long-term follow-up from IMROZ included findings on MRD dynamics with quadruplet frontline therapy in multiple myeloma.

Early phase 2 results suggest 12-cycle pirtobrutinib–obinutuzumab yields high responses in untreated CLL with minimal cardiac effects.

It was previously shown that the STELLAR-303 trial achieved the coprimary end point of OS in the ITT population.

Results from the SPEARHEAD-1 trial supported FDA approval of the engineered T-cell product for patients as young as 12 years of age.

The investigational ADC sigvotatug vedotin missed the primary OS endpoint vs docetaxel in phase 3 NSCLC trial, but showed stronger second-line benefit trends.

Dr Haigentz breaks down 3 practice-changing ASCO 2026 lung cancer abstracts, from adjuvant targeted therapy to ADCs reshaping the immunotherapy backbone.

Glioblastoma treatment still stalls beyond Stupp, while meningioma lacks systemic salvage options; Singh highlights adaptive trials, molecular profiling, and young-patient quality-of-life risks.

An ongoing dose expansion phase of the trial is evaluating CRB-701 plus pembrolizumab for first-line OPSCC.

Blood-based T‑cell receptor sequencing reveals immune “fingerprints” in Lynch syndrome, helping track precancers early and paving the way for new cancer surveillance biomarkers.

How young women with lung cancer face stigma, misdiagnosis, and fertility gaps—plus the equity-driven approach reshaping care and trials.

MD Anderson trial uses psilocybin-assisted therapy to help head and neck cancer patients cope with trauma and improve recovery.

During a live event, Sapna Patel, MD, discussed how to sequence second-line therapy for a patient with BRAF-mutant melanoma after immunotherapy and targeted therapy.

The patients with HNSCC had already been treated with immune checkpoint inhibitors and platinum-based chemotherapy.

Puxitatug samrotecan is now being evaluated in the global phase 3 BLUESTAR-Endometrial-01 trial.

Real-world claims data show alectinib beats crizotinib in ALK+ NSCLC survival, urging early use of newer ALK inhibitors.

"These findings support carboplatin-based IC-CCRT as a promising alternative treatment option for LA-NPC," Jian Guan, MD.

A scoring tool combining frailty, chronological age, and comorbidities showed distinct outcomes among patients who received allogeneic hematopoietic cell transplant.

FDA reviews chemo-free mosunetuzumab plus polatuzumab for relapsed/refractory LBCL, promising outpatient second-line care and longer PFS.

ASCO 2026 highlights breast cancer care: gene tests help skip chemo, new SERDs and ADCs improve outcomes, ctDNA guides earlier switches.

Updated NCCN guidelines now recommend CSF-based genomic profiling for biopsy-infeasible high-grade gliomas and glioblastomas, expanding liquid biopsy use in CNS cancer.

During a live event, Prerna Mewawalla, MD, and participants discussed selecting therapy for patients with early relapsed/refractory multiple myeloma who are not candidates for CAR T-cell therapy.

Ofirnoflast is a first-in-class oral allosteric modulator of NEK7 that previously received FDA orphan drug designation.

At the EHA 2026 Congress, researchers presented novel treatments and combinations for newly diagnosed multiple myeloma, relapsed disease, and smoldering myeloma.

A phase 3 trial of givastomig is expected to begin as early as the fourth quarter of 2026.